We are a pioneer in developing novel therapeutics aimed
at treating neurological and neuropsychiatric brain disorders.
GliaCure is focused on the development of novel therapies for neurological and neuropsychiatric disorders based on glia targets. GliaCure was founded in 2011 and is based on discoveries by its scientific founder, Philip Haydon, Ph.D., of Tufts University. Professor Haydon has partnered with Michael Szulczewski, who successfully co-founded the imaging company Prairie Technologies, Inc. GliaCure has successfully completed a Phase 1 Human Trial of its small molecule that shows promise in treating Alzheimer’s.
GliaCure is a pioneer in the development of novel therapeutics aimed at treating neurological and neuropsychiatric disorders of the brain. The company’s approaches are based on glial targets, a cell type in the brain that has previously been overlooked in drug discovery…more »
26
Apr 2019
GliaCure has successfully closed it’s Seed C financing round, GliaCure has raised over $11 million to date from private investors and charitable foundations such as ADDF . GliaCure will be presenting at the NeuroTech Investing and Partnering Conference on May 21, 2019 in Boston, Massachusetts.